10-K Filing

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC CIK: 1730430 FY 2019

Filing Information

Form Type	10-K
Accession Number	`0001558370-20-002081`
Period End Date	20191231
Filing Date	20200305
Fiscal Year	2019
Fiscal Period	FY
XBRL Instance	knsa-20191231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 49 Income Statement 28 Cash Flow Statement 54 Stockholders Equity 17

Balance Sheet 49 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$46.93M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$71.98M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$186.45M	USD	Point-in-time
Short-term investments	`ShortTermInvestments`	$235.33M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$8.25M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$6.45M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$313.75M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$241.63M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.40M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$6.36M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$1.93M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$210.00K	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	-	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	$433.00K	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$1.22M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$4.37M	USD	Point-in-time
Total assets	`Assets`	$321.96M	USD	Point-in-time
Total assets	`Assets`	$254.53M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.69M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$10.92M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$16.42M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$20.41M	USD	Point-in-time
Accrued milestones	`AccruedMilestoneLiabilitiesCurrent`	$15.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.70M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$218.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$25.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$27.83M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$42.55M	USD	Point-in-time
Noncurrent operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$955.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$326.00K	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$144.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$42.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$29.11M	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$473.48M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$581.47M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$33.00K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-194.22M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-356.09M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$279.27M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$225.42M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$321.96M	USD	Point-in-time
Total liabilities and shareholders equity	`LiabilitiesAndStockholdersEquity`	$254.53M	USD	Point-in-time

Income Statement 28 line items

Line Item	Tag	Value	Unit	Period
Research and development expense	`ResearchAndDevelopmentExpense`	$86.60M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$135.00M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$21.56M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$34.96M	USD	Annual
Total operating expenses	`OperatingExpenses`	$108.16M	USD	Annual
Total operating expenses	`OperatingExpenses`	$169.96M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-169.96M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-108.16M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$6.05M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$4.72M	USD	Annual
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-163.91M	USD	Annual
Loss before benefit for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-103.44M	USD	Annual
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-2.05M	USD	Annual
Benefit for income taxes	`IncomeTaxExpenseBenefit`	$-214.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-161.87M	USD	Annual
Net loss	`NetIncomeLoss`	$-103.23M	USD	Annual
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-2.99	USD	Annual
Net loss per share attributable to common shareholders - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-3.49	USD	Annual
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	29.55M	shares	Annual
Weighted average common shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	54.05M	shares	Annual
Net loss	`NetIncomeLoss`	$-161.87M	USD	Annual
Net loss	`NetIncomeLoss`	$-103.23M	USD	Annual
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$37.00K	USD	Annual
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.00K	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-4.00K	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$37.00K	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-103.23M	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-161.83M	USD	Annual

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-103.23M	USD	Annual
Net loss	`ProfitLoss`	$-161.87M	USD	Annual
Depreciation expense	`Depreciation`	$2.07M	USD	Annual
Depreciation expense	`Depreciation`	$286.00K	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$15.08M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$5.70M	USD	Annual
Class A common shares issued or to be issued as consideration for Primatope, including milestone payments	`IssuanceOfStockForAcquisition`	$8.80M	USD	Annual
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-66.00K	USD	Annual
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-21.00K	USD	Annual
Other	`OtherNoncashExpense`	$235.00K	USD	Annual
Non-cash lease expense	`NoncashLeaseExpense`	$1.21M	USD	Annual
Accretion of discounts on short-term investments	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.50M	USD	Annual
Accretion of discounts on short-term investments	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$1.42M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-3.16M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-978.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.02M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$4.79M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-4.71M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$8.82M	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$4.64M	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilities`	$9.30M	USD	Annual
Accrued milestones	`IncreaseDecreaseInAccruedMilestone`	$5.00M	USD	Annual
Accrued milestones	`IncreaseDecreaseInAccruedMilestone`	$-15.00M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-1.26M	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$326.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-81.01M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-158.37M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$5.29M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$3.20M	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$402.01M	USD	Annual
Purchases of short-term investments	`PaymentsToAcquireShortTermInvestments`	$488.77M	USD	Annual
Proceeds from the maturities of short-term investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments`	$541.19M	USD	Annual
Proceeds from the maturities of short-term investments	`ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments`	$168.10M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-239.20M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$49.21M	USD	Annual
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$118.00K	USD	Annual
Payments of offering costs	`PaymentsOfStockIssuanceCosts`	$3.66M	USD	Annual
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$377.00K	USD	Annual
Proceeds from exercise of options and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$1.12M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$84.11M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$346.74M	USD	Annual
Net increase in cash and cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$26.53M	USD	Annual
Net increase in cash and cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-25.05M	USD	Annual
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.14M	USD	Point-in-time
Cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$45.66M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$72.19M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.14M	USD	Point-in-time
Cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$45.66M	USD	Point-in-time
Cash paid for income taxes	`IncomeTaxesPaid`	$1.72M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaid`	$383.00K	USD	Annual
Deferred offering costs included in accrued expenses and accounts payable	`DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable`	$404.00K	USD	Annual
Property and equipment included in accrued expenses and accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$222.00K	USD	Annual
Property and equipment included in accrued expenses and accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$1.29M	USD	Annual

Stockholders Equity 17 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$225.42M	USD	Point-in-time
Balance at the beginning of the period	`StockholdersEquity`	$-89.71M	USD	Point-in-time
Conversion of convertible preferred shares into common shares	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$310.59M	USD	Annual
Common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.	`StockIssuedDuringPeriodValueAcquisitions`	$7.00M	USD	Annual
Common shares issued or to be issued in connection with a milestone payment due to Primatope Therapeutics, Inc.	`StockIssuedDuringPeriodValueMilestonePayments`	$1.80M	USD	Annual
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$377.00K	USD	Annual
Exercise of options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.12M	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$5.70M	USD	Annual
Share-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$15.08M	USD	Annual
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$37.00K	USD	Annual
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-161.87M	USD	Annual
Net loss	`NetIncomeLoss`	$-103.23M	USD	Annual
Balance at the end of the period	`StockholdersEquity`	$279.27M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$225.42M	USD	Point-in-time
Balance at the end of the period	`StockholdersEquity`	$-89.71M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.